Download Research - Par For The Cure

JCCF News
Spring/Summer 2007
A Publication of the Jonsson Cancer C e n t e r F o u n d a t i o n a t U C L A
R
esearchers at the Jonsson
Comprehensive Cancer
Center (JCCC) are continuing
their diligent efforts to discover
the keys to prevent and more successfully treat
melanoma, one of the fastest growing forms
of cancer.
The development of new targeted therapies
is greatly needed due to spiraling diagnosis rates
and limited treatment options for the disease.
The number of melanoma cases is increasing
faster than any other type of cancer as more
non-Caucasian populations become affected
with the disease. The American Cancer
Society estimates that 62,000 Americans will be
diagnosed with melanoma this year. Presently,
there are few effective treatment alternatives to
surgery for this aggressive type of cancer.
"This is bound to change, thanks to the
wealth of knowledge we now have about the
molecular mechanisms that guide this cancer and
SYVVI½RIHYRHIVWXERHMRKSJLS[XLIMQQYRI
W]WXIQGERLIPT½KLXMXWE]W%RXSRM6MFEW1(
a member of JCCC's Tumor Immunology
Program Area, associate professor of hematology/
oncology and a top melanoma researcher at UCLA.
6IGIRXIJJSVXWMRQIPERSQEVIWIEVGL
focusing on monoclonal antibodies, sentinel
lymph nodes and immunotherapy have created
new hope for the development of the next
generation of prevention and treatment alternatives.
Vaccine Fights Melanoma
JCCC researchers have conducted Phase I/II
trials of a therapeutic vaccine for melanoma that
QE\MQM^IWXLIREXYVEPGERGIV½KLXMRKEFMPMXMIWSJ
the patient's immune system. A unique vaccine
is created at the JCCC using the patient's own
cells, which are manipulated to recognize
QIPERSQEWTIGM½GTVSXIMRW8LIGIPPWEVI
injected into the patient, thereby stimulating
1IPERSQE
6IWIEVGLIVW
Gain Ground
UCLA Melanoma Researcher Antoni Ribas, M.D.
"
The number of
melanoma cases
is increasing
faster than any other
type of cancer . . .
"
the patient's natural immune system to begin
½KLXMRKXLIQIPERSQE8LIVIWYPXWWLS[
promise, including, in one patient, the disappearance
of melanoma within three months.
"Our success in engineering a reversal of the
immune suppression may lead to ways to protect
melanoma patients before their cancers attempt
to spread, offering a much needed alternative
XSWYVKIV]WEMH%PMWXEMV'SGLVER1(E
professor of pathology and laboratory medicine
Continued on page 2
Taste for a Cure
The Jonsson Cancer Center
Foundation's (JCCF) signature
fundraising event, Taste for a Cure, is
slated for Saturday, June 16 at the Beverly
Wilshire Hotel. Jay Sures, a partner and
Board member at United Talent Agency,
will be presented with the Gil Nickel
Humanitarian Award for his commitment
to philanthropy, humanitarian efforts and
community involvement. The award was
established in 2004 in memory of event
supporter Gil Nickel, founder and
proprietor of Far Niente, Nickel & Nickel,
and Dolce Wineries. Marilyn and Jeffrey
Katzenberg, CEO and Director of
DreamWorks Animation SKG, and Caryn
and Jeff Zucker, President and CEO of
NBC Universal, will serve as Dinner
Co-Chairs, and Judd Apatow, producer/
director/writer, will host the evening.
Celebrating its 12th year, the
popular event boasts some new twists
while retaining many of the traditions
that have long made it a success. With
premium California wines, savory hors
d'oeuvres and a decadent dinner
prepared by some of LA's top women
chefs, it promises to be a luxurious
evening. A special wine and food
tasting reception, featuring hors d'oeuvres
celebrating the diversity of Los Angeles
GYMWMRITEMVIH[MXLßRI[MRIWJVSQXST
women vintners, opens the evening,
followed by a three-course dinner hosted
by Conny Andersson, executive chef at
the Beverly Wilshire. Live and silent
auctions offer standout items and
enticing packages. In addition, the JCCF
expands its reach into the community
[MXLMXWßVWXSRPMRIEYGXMSRSTIRXSXLI
general public through CharityFolks.com.
Since its inception, the event has
raised more than $4.7 million for the
Jonsson Cancer Center's highest
priority cancer research.
Tickets to Taste for a Cure begin at
$500. Table sponsorships start at $5,000.
For tickets and information, please
call Levy, Pazanti & Associates at
(310) 201-5033.
Inside
Research News
Awards Announced
Foundation Giving
Donors Recognized
Limelight
2
3
4
5
6
(MVIGXSV´W'SVRIV
Y
ou may have heard
recently that cancer deaths
in the United States have
declined for the second
straight year. This is a very
promising trend, and it can be
attributed to improved prevention,
detection and treatment techniques.
I believe it is also a result of
private philanthropic support for
cancer research. At the Jonsson
Comprehensive Cancer Center
(JCCC), our aim is to forge
new ground in the understanding
and treatment of cancer. And
we have a longstanding record of
success in leveraging philanthropic
JLIWVIRUWKHEHQHÀWRI FDQFHU
patients and survivors.
These gifts often result from
one person's dedication to making
a difference. This issue of JCCF
News mentions a few of these
individuals by name, including
Kathy Goldring-Fromberg, who
mobilized a vast network
of family and friends to help
1IPERSQE6IWIEVGLIVW
launch the UCLA Sarcoma
Program (see article at right).
Another example is Lottie
McKnight, a woman of
modest means, who left most
of her estate to the JCCC to
underwrite research opportunities
for future cancer scientists (see
page 4). In addition, the JCCC's
namesake, Ken Jonsson, has once
again chosen to further the cause
of cancer research by creating a
generous endowment that also
honors the memory of his wife,
Diana Gordon Jonsson (see page 4).
Their legacy – and yours
through your steadfast support –
will be continued improvements
in cancer survival rates. Thank
you for making good news about
cancer possible.
Judith C. Gasson, Ph.D.
Director, Jonsson Comprehensive
Cancer Center
Continued from cover
and surgery who conducts melanoma research at UCLA.
(IWTMXIXLIMQTVIWWMZIVIWYPXWXLIQERTS[IVERHGSWXW
EWWSGMEXIH[MXLXLIGVIEXMSRSJTEXMIRXWTIGM½GZEGGMRIWQEOI
the treatment impractical for widespread use and underscore
the necessity of further research.
In addition, JCCC melanoma researchers are examining
EWTIGM½GQSRSGPSREPERXMFSH]'4XLEXEXXEGOW
CTLA-4, a protein that can act as a switch for the body's
immune system. In a Phase I trial, about half of the patients
[LSVIGIMZIHXLILMKLIWXHSWISJ'4I\TIVMIRGIHE
durable regression from melanoma.
Alistair Cochran, M.D.
Fellowship Established
Providing a boost to research efforts, the V Foundation-Gil Nickel Fellowship
MR1IPERSQE6IWIEVGL[EWVIGIRXP]IWXEFPMWLIHMRLSRSVSJXLIPEXI+MP2MGOIPE
long-time JCCC supporter. The goal of the fellowship, funded through an
endowment, is to recruit and train a new generation of promising young
researchers at the JCCC to conduct melanoma research that may translate
laboratory breakthroughs into pre-clinical and clinical testing of novel
treatments for patients.
9RHIVXLIHMVIGXMSRSJ6MFEW[LS[MPPVIGVYMXXLIRI[VIWIEVGLIVWXLIJIPPS[W
can become involved in melanoma research in a variety of areas, such as gene medicine,
vaccine research, targeted therapies, basic research and clinical trials.
;MXLWXITTIHYT½RERGMEPGSQQMXQIRXERHMRGVIEWIHVIWIEVGLIJJSVXW
scientists believe it is only a matter of time before major new advances in
melanoma prevention and treatment are realized.
2 JCCF News
Sarcoma Program
Leaps to Top
I
RMXW½VWX]IEVXLI
UCLA Sarcoma
Clinical/Translational
6IWIEVGL4VSKVEQ
has become the
premier sarcoma referral
organization in the western
United States and one of
the three busiest in the
REXMSR1SVIXLER
adults and children at
all stages of the disease
Frederick (Fritz) Eilber, M.D.
have received evaluations
through the program, which offers an innovative
multidisciplinary approach for treating this rare cancer.
The program, a collaboration between the
Jonsson Comprehensive Cancer Center (JCCC), the
9'0%(MZMWMSRSJ,IQEXSPSK]3RGSPSK]ERHXLI
9'0%(MZMWMSRSJ7YVKMGEP3RGSPSK]FVMRKWXSKIXLIV
physicians and investigators from a range of medical
ERHWGMIRXM½GHMWGMTPMRIW7EVGSQEWTIGMEPMWXWJVSQ
surgical oncology, orthopedic oncology, medical
oncology, radiation oncology, pediatric oncology,
pathology and radiology meet weekly to formulate
and coordinate the most optimal and personalized
treatment strategies for patients.
Coordinating research and patient care fosters
interaction between doctors as well as between
doctors and their patients that creates an advantage
to treating sarcoma.
"The Sarcoma Program at UCLA offers patients
a truly personalized approach to their cancer care in
[LMGLQYPXMTPIHSGXSVWJVSQEVERKISJ½IPHWEVI
HIHMGEXIHXS½RHMRKXLIVMKLXXVIEXQIRXJSVIEGL
TEXMIRXWXEXIW*VIHIVMGO*VMX^)MPFIV1(EWYVKMGEP
oncologist and director of the Sarcoma Program.
%HHW;MPPMEQ8ET1(EQIHMGEPSRGSPSKMWX[LS
co-leads the program with Eilber, "By closely aligning
translational laboratory studies and clinical trials, we
LEZIGVIEXIHETEXLXS½RHQSVIIJJIGXMZIXLIVETMIW
for sarcoma patients. Patients have the opportunity
to be involved in groundbreaking studies, including
innovative targeted treatments that destroy
cancer cells without harming healthy tissue."
The Sarcoma Program is an extension of the
PEXI/EXL]+SPHVMRK*VSQFIVKWHIHMGEXMSRERH
HIXIVQMREXMSRXS½KLXLIVS[RFEXXPIEKEMRWXWEVGSQE
The Goldring and Fromberg families and their friends
LEZIVEMWIHQSVIXLERMRXVMFYXIXSLIV
She has been duly honored with one of the
country's foremost Sarcoma treatment and research
centers, which offers the gift of hope for others
½KLXMRKXLIHMWIEWI
For more information about sarcoma clinical trials
and treatment options, please contact Sheila Stinnett,
Clinical Specialist at the UCLA Sarcoma Program,
at (310) 825-7086.
JCCF News is published semi-annually by
the Jonsson Cancer Center Foundation
Editor: Libby Huebner
Contributors: Jill Allison, Penny Amescua, SiUn Cha,
7LIMPE1G(ERMIP,IRV]8IVVM,SPPERH/MQ-V[MR%QFIV.E[EMH
/EXLPIIR.SWI/EXL]7ERGLI^ERH']RXLME7LITTEVH
Photographers: Joanie Colton, Elissa Hofelt, Steve Levesque,
3TTYPIRGI7XYHMSW/EXL]7ERGLI^ERH.YPMI7SWOI
Design: ,SJIPX(IWMKR
S
C
C
C
be
ca
ha
m
to
ca
vit
co
po
an
JC
Ab
w
an
un
co
St
m
ho
it
gu
pa
92
ar
ca
ev
ap
ne
JCCF
Excellence in
Research
Significant Faculty Awards & News
Amander Clark, Ph.D., a member of the JCCC Cancer Cell
&MSPSK]4VSKVEQ%VIEVIGIMZIHE'EVIIV(IZIPSTQIRX%[EVHJVSQ
7834'%2')6
Paul Mischel, M.D., a member of the JCCC Signal Transduction and
Therapeutics Program Area, was honored with the Farber Award,
presented by the American Association of Neurological Surgeons and
the Society for Neuro-Oncology.
JCCC Signal Transduction and Therapeutics Program Area member
David Wong, D.M.D., D.M.Sc., was named a Fellow of the
American Association for the Advancement of Science.
UCLA’s Jonsson Cancer Center Foundation
(JCCF) proudly announces the recipients of its
annual Seed Grants and Fellowship Awards.
Congratulations to the following JCCC
members for their outstanding contributions
XSXLIßIPHSJGERGIVVIWIEVGL
Fellowship Awards
Ron Birnbaum (Noah Craft, M.D., Ph.D.*)
1IPERSQE6IWIEVGL– "Imidazoquinoline Potentiation
SJE6IGSQFMRERX0MWXIVME1SRSG]XSKIRIW:EGGMRIJSV
1IPERSQEVSPISJITMXSTIWTVIEHMRK
Xiaoyu Zhang (Steve Jacobsen, Ph.D.*)
&EWMG6IWIEVGL– "+IRSQI[MHIHIXIGXMSRSJ(2%
methylation in normal and cancer tissues"
Meredith Oltmann (Geraldine Weinmaster, Ph.D.*)
&EWMG6IWIEVGL– "Characterization of mutant mice
defective in Notch 1 furin processing"
* Principal Investigator
Seed Grant Awards
Miriam Laugesen, Ph.D.
Cancer Prevention – "1ERHEXIH-RWYVERGI'SZIVEKIJSV
Breast, Cervical, Colon and Prostate Cancer Screening"
George Thomas, M.D.
/MHRI]'ERGIV6IWIEVGL– "4IVWSREPM^MRKQ836MRLMFMXSV
therapy in kidney cancer through biomarker
MHIRXM½GEXMSR
Early Stage Breast
Cancer Survival
Increased
Colorectal
Cancer Surgery
Care Safeguards Set
In an effort to improve patient care
before, during and after colorectal
cancer surgery, UCLA researchers
have developed a checklist of quality
measures that can be used by physicians
to safeguard patients' care.
Improving the quality of surgical
care for colorectal cancer patients is
vital since the number of resections
continues to increase in an aging
population, according to Clifford Ko, M.D.,
an associate professor of surgery and
JCCC researcher, who headed the study.
About 148,000 people will be diagnosed
with colorectal cancer this year alone,
and about 90 to 95 percent of those will
undergo surgery.
Colorectal cancer is the second most
common cancer diagnosed in the United
States and is treated at major academic
medical centers as well as in community
hospitals and surgical centers. Because
it is treated in so many different places,
guidelines outlining the best care for
patients provide a valuable tool.
Ko and his colleagues came up with
92 quality of care indicators in six broad
areas that cover all aspects of surgical
care, ranging from a patient's health
evaluation before surgery to the most
appropriate surgical techniques. The
new quality indicators also detail
Awards Announced
J
Clifford Ko, M.D.
the best post-operative patient
management practices.
"You can do the best operation in
the world, but it doesn't mean much
if the patient doesn't do well after
surgery," Ko said.
Ko and his team hope the quality
indicators will be used as a checklist
by surgeons and others in the
community caring for colorectal
cancer surgery patients. Healthcare
professionals may already be doing
some of the things on the checklist,
but the quality measures could
serve as a safeguard to ensure that
everything that should be done
actually gets done.
The new quality indicators
will be distributed to healthcare
professionals in the community in
CD form. Additionally, UCLA
researchers will present their work
at conferences and meetings in
order to raise awareness.
onsson Comprehensive Cancer
Center (JCCC) researchers have
discovered that combining the
molecularly targeted therapy
Dennis Slamon, M.D., Ph.D.
Herceptin with chemotherapy in
women with early stage breast
cancer significantly improves disease-free survival for patients
who have a specific genetic mutation, HER-2 positive, which
results in a very aggressive form of the disease. The results,
based on a Phase III study of more than 3,200 women, were
reported by Dennis Slamon, M.D., Ph.D., whose laboratory
and clinical research led to the development of Herceptin.
The three-armed study compared the standard therapy
of Adriamycin and Carboplatin followed by Taxotere (ACT),
an experimental regimen of Adriamycin and Carboplatin
followed by Taxotere and one year of Herceptin (ACTH),
and an experimental regimen of Taxotere and Carboplatin
with one year of Herceptin (TCH).
The study tested Herceptin with and without Adriamycin,
an anthracycline commonly used to treat breast cancer but
one that can cause permanent heart damage, particularly
when paired with Herceptin. Researchers wanted to
determine whether they could provide a therapy as
effective as ACTH without the resulting cardiac problems.
"This study demonstrates unequivocally that the best
treatment for early stage HER-2 positive breast cancer is
obtained with a non-anthracycline regimen, TCH, that avoids
the significant cardiac damage found when Adriamycin is
used with Herceptin," said Slamon, director of clinical/
translational research at the JCCC. "This trial should impact
the way early stage breast cancer is treated, with TCH being
considered the preferred option."
Spring/Summer 2007
3
Foundation
Diana Jonsson
Legacy Continues
Giving
8LI(MERE+SVHSR.SRWWSR(MVIGXSVW
)RHS[QIRX*YRHMRQIQSV]SJ(MERE
Gordon Jonsson has been created with
EWMKRM½GERXKMJXJVSQLIVLYWFERH/IR8LI
IRHS[QIRX[MPPLSRSV(MEREWQIQSV]F]
underwriting the annual Jonsson Cancer
'IRXIV*SYRHEXMSR(SRSV6IGSKRMXMSR
(MRRIVERHTVSZMHMRKXLVSYKLX[SWTIGMEPE[EVHW
public recognition of the Jonsson Comprehensive
'ERGIV'IRXIVW½RIWXMRZIWXMKEXSVWERHMXW
courageous patients who are battling cancer
on the front lines.
8LI(MERE+SVHSR.SRWWSR%[EVHJSV'PMRMGEP
Excellence will be presented each year to a JCCC
oncologist who lifts his or her patients emotionally as
well as physically. The award includes a grant, funded
by interest from the endowment, to be directed to the
recipient's highest priority research needs.
-REHHMXMSRXLI(MERE+SVHSR.SRWWSR%[EVHJSV
Hope and Inspiration will be presented annually to a
JCCC Director Judith Gasson, Ph.D., addresses guests at the
annual Donor Recognition Dinner, which will be underwritten by
the Diana Gordon Jonsson Directors Endowment Fund.
GERGIVTEXMIRX[LSI\IQTPM½IWXLIWTMVMXSJWYVZMZEPERH
whose battle with cancer serves as a model for others.
8LIIRHS[QIRXERHXLIX[SVIPEXIHE[EVHWVI¾IGX
(MEREWWIRWISJ[EVQXLMRXIPPMKIRGIERHKIRYMRI
concern for others. There is no doubt that her legacy
will continue to inspire and bring hope to cancer
patients and members of the philanthropic community.
Planned Gift Supports Seed Grants
A new source of funding is now
available for Jonsson Comprehensive
Cancer Center (JCCC) investigators
thanks to a planned gift made by long-time
Thousand Oaks resident Lottie McKnight.
In 2002, McKnight worked with the
Jonsson Cancer Center Foundation to
include a provision in her living trust for the
creation of the Lottie E. Grimm McKnight
Fund for Young Cancer Researchers.
Beginning this spring, the McKnight
Fund will provide $40,000 annually for
T
Lifeline Challenge Succeeds
he Jonsson Cancer Center Foundation (JCCF)
NLFNHGRIILWVÀUVWHYHU0DWFKLQJ&DPSDLJQ
Challenge at the Petersen
$XWRPRWLYH0XVHXPRQ
6HSWHPEHU&R
VSRQVRUHGE\3HJJ\%ORRPÀHOG
and the John and Ursula Kanel
&KDULWDEOH)RXQGDWLRQWKH1HZ0HPEHU0DWFKLQJ
&KDOOHQJHSURYLGHVDGROODUIRUGROODUPDWFKIRUDQ\
donations from new Lifeline Connection members.
6RIDUWKHFDPSDLJQKDVEHHQYHU\VXFFHVVIXO,QWKH
ÀUVWVL[PRQWKV/LIHOLQH&RQQHFWLRQJDLQHGQHZ
4 JCCF News
fellowship and research grants for junior
investigators at the JCCC.
Planned gifts, including bequests,
charitable remainder trusts and gift
annuities, offer a unique opportunity to
support cancer research. Often, these
gifts have no effect on the donor's current
ßRERGIWERHGERTVSZMHIWIGYVMX]JSVPSZIH
ones as well as minimize estate taxes.
To learn more about planned gift
options or to include JCCF in your estate
plans, please contact Sheila Henry, JCCF
Director of Special Gifts, at (310) 794-7647.
members, who contributed more than $112,000,
which will be matched. The funds raised by the
Challenge, as well as all other Lifeline
Connection donations, will be used to
support highest priority research at the
-RQVVRQ&RPSUHKHQVLYH&DQFHU&HQWHU
including seed grants. The JCCF thanks
3HJJ\%ORRPÀHOGWKH-RKQDQG8UVXOD.DQHO
&KDULWDEOH)RXQGDWLRQDQGDOOWKRVHZKRKDYHKHOSHG
to make the Challenge campaign such a success.
To join Lifeline Connection now, please call
Terri Holland at (310) 794-7617.
Chairman’s Letter
A
ll of us who
support worldclass cancer
research at the Jonsson
Comprehensive Cancer
Center (JCCC) receive
great satisfaction in
return. We know that our gifts are
helping to develop better prevention
strategies, diagnostic tools and
treatment options for cancer patients
and their families. The fact that we
EPWSVIGIMZIXE\FIRI½XWJSVSYV
contributions is an added reward.
Last year, Congress created a new
[E]XSIRGSYVEKIGLEVMXEFPIKMZMRK
the Pension Protection Act of 2006. It
MWWTIGM½GEPP]HMVIGXIHEXHSRSVWSJVItirement age who are not dependent on
XLIMV-RHMZMHYEP6IXMVIQIRX%GGSYRXW
-6%WJSVPMZMRKI\TIRWIW-JXLITVS½PI
FIPS[VI¾IGXW]SYVWMXGSYPHFI[SVXL
your time to learn more about these
RI[VYPIW
=SYEVI]IEVWSJEKISVSPHIV
2) You are required to take
YRRIGIWWEV]-6%[MXLHVE[EPWSV
you have experienced limitations on
XE\FIRI½XWMRXLITEWXJSVEZEVMIX]
SJVIEWSRW
3) You want to give any amount up to
$100,000 from traditional or
6SXL-6%WHMVIGXP]XSUYEPM½IH
charities, such as the Jonsson
Cancer Center Foundation (JCCF),
MRXLIGEPIRHEV]IEV
-J]SYUYEPMJ]]SYGERWIRH]SYV-6%
funds directly (without withdrawing
them and reporting them as income)
to charities. In this way, you can give
generously to your philanthropic
causes and avoid paying taxes on the
gifts at the same time. For many, the
Pension Protection Act may offer new
opportunities for tax-free charitable
giving to the JCCF and other charitable
MRXIVIWXWMR8LITVSZMWMSRWSJXLMW
new law will affect individuals differently,
so I encourage you to consult with your
advisors. The Pension Protection Act is
WPEXIHXSI\TMVIEXXLIIRHSJWS
please act now.
Thank you for your consideration and
continued generosity to the JCCF.
William M. Bitting
Chair of the Board
Jonsson Cancer Center Foundation
Gifts of Note
UCLA's Jonsson Cancer Center Foundation is honored to
recognize the following donors for their generous support:
$2,500,000+
The Entertainment Industry Foundation
Breast Cancer Research, Colorectal Cancer
Research, and Revlon/UCLA Women's
Cancer Research Program
$1,000,000 - $2,499,999
s
t
on
½PI
XL
The Kenneth Jonsson Family Foundation
The Diana Gordon Jonsson Directors
Endowment Fund
V Foundation for Cancer ResearchGil Nickel Family
V Foundation-Gil Nickel Fellowship
in Melanoma Research
o
City of Chula Vista
Breast Cancer Research
Virginia and Walter Sawicki
Basic Cancer Research
United Cancer Front
Clinical/Translational Research
$250,000 - $499,999
0UV0DUJDUHW0%ORRPÀHOG
JCCC Highest Priority Needs
STOP CANCER
Research Career Development Awards
Anonymous
Translational Cancer Research
Avon Foundation
Breast Cancer Research
and
Wendy and Ken Ruby
Leukemia Stem Cell Discovery Research and
JCCC Highest Priority Needs
Harry Allgauer Foundation
Brain Cancer Research
$100,000 - $249,999
ble
XLMW
ntly,
your
t is
WS
Capitol Records Group, Inc.
JCCC Highest Priority Needs
$50,000 - $99,999
F),
w
Par for The Cure
Translational Breast Cancer Research
Biastre Family Trust
JCCC Highest Priority Needs
Denise and Peter Wittich
Translational Breast Cancer Research
)
%LOODQG3DWWL%ORRPÀHOG
JCCC Highest Priority Needs
$500,000 - $999,999
Michele and George Michael Richman
Gastrointestinal Cancer Research
on
X]
Philip R. Jonsson Foundation
Brain Cancer Research
Blue Cross Foundation of California
Cancer Survivorship Research
Robert A. Day
Revlon/UCLA Breast Center
The John and Ursula Kanel Charitable Foundation
JCCC Highest Priority Needs
Saul Rosenzweig
in memory of Carol Rosenzweig
Ted Mann Family Resource Center
and JCCC Highest Priority Needs
Conejo Valley Guild of JCCF
JCCC Highest Priority Needs
Expedition Inspiration Fund
for Breast Cancer Research
Revlon/UCLA Breast Center
The Green Family Foundation
Leukemia Stem Cell Discovery Research
and JCCC Highest Priority Needs
Kasdan Family Foundation
Pediatric Oncology and JCCC
Highest Priority Needs
Alstyne E. and Frances A. Pruner Foundation
JCCC Highest Priority Needs
Shelley P. Resnik
Squamous Cell Carcinoma Research and
Ted Mann Family Resource Center
Jane and Terry Semel
Revlon/UCLA Women's Cancer Research Program
R. A. Stranahan Jr. Charitable Foundation
UCLA Family Cancer Registry and Genetics
Evaluation Program
Birches Foundation
in memory of Marlowe Cole
JCCC Highest Priority Needs
$25,000 - $49,999
Anonymous
JCCC Highest Priority Needs
Target
JCCC Highest Priority Needs
Thelma L. Culverson
Thelma L. Culverson Endowment
for Excellence in Cancer Research
Anonymous
in memory of Richard Green
Gastrointestinal Cancer Research and
JCCC Highest Priority Needs
Laura Ziskin and Alvin Sargent
Revlon/UCLA Women's Cancer Research
Program and JCCC Highest Priority Needs
Clarann and Irwin Goldring
UCLA Sarcoma Clinical/
Translational Research Program
Gifts and Pledges Received from March 1, 2006 to February 28, 2007
Kathleen and William Bitting
JCCC Highest Priority Needs
n
Spring/Summer 2007
JCCF 0 - 1 ) 0 - + , 8
Kudos to our community friends who
raise money for vital cancer research
at the Jonsson Comprehensive
Cancer Center.
(l-r) JCCC's Dennis
Slamon, M.D., Ph.D.,
and Brian Esposito
2nd Annual Par for The
Cure Celebrity Classic on
October 14 and 15, 2006
at TPC at the Canyons in
Las Vegas, Nevada, organized
by Brian Esposito, raised
$150,000 for breast cancer
research at JCCC.
(l-r) The entertainer
Mr. Hajee with Stage IV
breast cancer survivor
JoAnn Esposito and
Brian Esposito
Chris Cain,
director of
UNLV's
Professional
Golf Management
Program
Avon Walk for Breast Cancer on
September 16 and 17, 2006 in Los
Angeles contributed $150,000 for
breast cancer research at JCCC.
Participants cheer at Avon Walk for Breast Cancer
2nd Annual Kevin's Cancer Ride,
a dirt bike ride organized by Kevin
McKeehan on November 24, 25 and
26, 2006 in the Mojave Desert,
contributed $3,600 for JCCC's
highest priority cancer research.
(l-r) Aaron Andree, 11, Kevin McKeehan, 12, Justin Nine, 12, and
Sean McKeehan, 10, rode a combined 757 miles
Kicking up sand
60th Annual Touch of Holiday Splendor on
December 3, 2006 at the Odyssey Restaurant in
Granada Hills, organized by the San Fernando Valley
Guild, raised more than $39,000 for JCCC's highest
priority cancer research.
(l-r) Guild members Shirley Eisner and
June Phillips assist a guest
(l-r) New San Fernando Valley Guild member
Mary Fontana and Guild President Margaret Hill
6 JCCF News
Holiday tree raffle
BreastFest 2006, an annual rock
concert organized by Stephen Staats,
featuring an acoustic performance
by Gerina Di Marco and a Yamaha
guitar auction on November 16, 2006
at The Gig in Hollywood, contributed
more than $1,200 to breast cancer
research at JCCC.
(l-r) Esther Staats and
Stephen Staats with
Gerina Di Marco and
Chris DeStefano
Kathy's Club Boutique, held in memory of
Kathy Goldring-Fromberg on November 2, 2006
at the Hyatt Valencia in Valencia, contributed
$5,500 to support the UCLA Sarcoma Clinical/
Translational Research Program at JCCC.
nt
JCCC information displayed
at Kathy's Club Boutique
SPJ & Pete Klaidman Memorial Golf
Tournament, organized by Bob Klaidman of SPJ
Lighting on December 11, 2006 at the Wilshire
Country Club in Los Angeles, raised more than
$6,500 for melanoma research at JCCC.
(l-r) Chad Dalgleish of CD Illuminations, Steven
Kinzler of SK Landscape, pro golfer Megan Heckeroth
and Bob Klaidman of SPJ Lighting
(l-r) Conejo Valley
Guild Co-Presidents
Shirley Brenner and
Beverly Halpern
(l-r) Guild members Susan Moses, Margarita Horwitz,
Ellen Bradshaw and Carol Amenta
San Fernando Valley Guild
2nd Annual Cruise for the
Cause, a fall foliage cruise along
the New England and Canadian
coastline from September 23
to 30, 2006, raised more than
$2,000 for JCCC's highest priority
cancer research.
(l-r) San Fernando Valley Guild members Evelyn Pittsenbarger
and Diane Bodemeijer with Ron Bodemeijer
22nd Annual Mystic Day
on November 11, 2006 at the
Hyatt Regency Westlake Plaza
in Thousand Oaks, hosted
by the Conejo Valley Guild,
raised more than $16,000 for
JCCC's highest priority cancer
research.
Boutique Chairman
Audrey Garfinkel
The JCCF Community Events Program consists
of numerous fundraising events and activities
coordinated by community organizations, businesses
and individuals. These events promote cancer
awareness as well as raise critical funds needed
to continue groundbreaking cancer research at
UCLA’s Jonsson Comprehensive Cancer Center.
If you are interested in selecting the JCCF as the
EHQH¿FLDU\RI\RXUIXQGUDLVLQJHYHQWSOHDVHYLVLW
www.jccf.mednet.ucla.edu/commevents.htm
RUFRQWDFWWKH6SHFLDO(YHQWV2I¿FHDW
(310) 794-2089 or [email protected].
Spring/Summer 2007 7
Calendar of Events
JCCC Contact Information
Jonsson Comprehensive Cancer Center
www.cancer.mednet.ucla.edu
May 2007
Friday, May 4 & Saturday, May 5
3DUIRU7KH&XUH%HQHÀW&RQFHUW
1HZ&DVWOH3$
&RQWDFW%ULDQ(VSRVLWR
ZZZSDUIRUWKHFXUHFRP
Jonsson Cancer Center Foundation
www.jccf.mednet.ucla.edu
Tuesday, May 8
&RQHMR9DOOH\*XLOGWK$QQXDO*DPH'D\
1RUWK5DQFK&RXQWU\&OXE:HVWODNH9LOODJH
&RQWDFW-RDQ&ROWRQ
JCCC Clinical Trial Website
www.cancer.mednet.ucla.edu/clinical-trials
Saturday, May 12
5HYORQ5XQ:DON)RU:RPHQ
([SRVLWLRQ3DUN/RV$QJHOHV
ZZZUHYORQUXQZDONFRP
June 2007
Sunday, June 3
:DOO\
V;9$QQXDO*UDQGH0DUTXH&KDPSDJQH7DVWLQJ
/H0HULJRW+RWHO6DQWD0RQLFD
&RQWDFW*DU\)LVKPDQ
Monday, June 11
6DQ)HUQDQGR9DOOH\*XLOGVW$QQXDO*ROI7RXUQDPHQW
/RV5REOHV&RXQWU\&OXE7KRXVDQG2DNV
&RQWDFW'DQ%RGHPHLMHU
Saturday, June 16
7DVWHIRUD&XUH-&&)6LJQDWXUH)XQGUDLVLQJ(YHQW
%HYHUO\:LOVKLUH+RWHO%HYHUO\+LOOV
&RQWDFW/HY\3D]DQWL$VVRFLDWHV
ZZZMFFIPHGQHWXFODHGXWDVWHIRUDFXUHKRPHKWP
Friday, June 30
*LIWVPXVWEHSRVWPDUNHGE\-XQHWRFRXQWIRU
-&&)
VÀVFDO\HDU
September 2007
Tuesday, September 11
-&&)'RQRU5HFRJQLWLRQ'LQQHU
7KH5HJHQF\&OXE/RV$QJHOHV
&RQWDFW-&&)6SHFLDO(YHQWV2IÀFH
Saturday, September 22
&UXLVLQ
)RU$&XUH
2UDQJH&RXQW\)DLU([SRVLWLRQ&HQWHU&RVWD0HVD
ZZZFUXLVLQIRUDFXUHFRP
October 2007
Saturday, October 6 - Saturday, October 13
6DQ)HUQDQGR9DOOH\*XLOGUG$QQXDO&UXLVHIRUWKH&DXVH
1LJKW*UHHN,VOHV&UXLVH
&RQWDFW(YHO\Q3LWWVHQEDUJHU
November 2007
Saturday, November 3
&RQHMR9DOOH\*XLOGUG$QQXDO0\VWLF'D\
+\DWW5HJHQF\:HVWODNH3OD]D7KRXVDQG2DNV
&RQWDFW%HYHUO\+DOSHUQ
December 2007
Sunday, December 2
6DQ)HUQDQGR9DOOH\*XLOGVW$QQXDO7RXFKRI+ROLGD\6SOHQGRU
2G\VVH\5HVWDXUDQW*UDQDGD+LOOV
&RQWDFW(YHO\Q3LWWVHQEDUJHU
9'0%1IHMGEP'IRXIV4L]WMGMER6IJIVVEPW
9'0%1(
www.ucla.edu/healthsci.html
Oncology Patient Services
32'9'0%
%ZIVEKI%RRYEP6IZIRYIERH)\TIRWIW
Donations to the Jonsson Cancer Center Foundation
(JCCF) have nearly tripled over the past decade. JCCF is
proud that since 1999 more than 90 cents of every dollar
has gone directly to cancer research at the JCCC.
JCCF Annual Revenue and Expenses
$12,000,000
$10,913,000
$10,000,000
$9,496,000
$8,000,000
$7,467,000
$6,000,000
$4,000,000
$3,579,000
$2,000,000
$0
$567,000
- Nick Valvano
&KLHI([HFXWLYH2I¿FHU
The V Foundation
(see cover story)
$1,017,000
Fiscal Years
Annual Expenses
Annual Revenue
JCCF News
Spring/Summer 2007
Box 951780
"
$861,000
1996-1998 1999-2001 2002-2004 2005-2006
8-950 Factor Building
Thanks to UCLA's renowned
team of researchers, the future
for melanoma patients is
brighter than ever.
$688,000
Los Angeles, CA 90095-1780
232463*-836+
U.S. POSTAGE
4%-(
UCLA
"